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Article Highlights 1 
 2 
Type of Research: Analysis of a multicenter randomized trial 3 
 4 
Key Findings: In this analysis of the ATTRACT Study, among patients with proximal DVT, 5 
pharmacomechanical catheter-directed thrombolysis (PCDT) with anticoagulation, compared with 6 
anticoagulation alone, had a beneficial effect on QOL during the first 6 months post-treatment (e.g. 7 
VEINES-QOL change scores were greater in PCDT vs. No PCDT from baseline to one month 8 
(difference 5.7; P=0.0006) and baseline to 6 months (5.1; P=0.0029). Further, among proximal DVT 9 
patients with iliofemoral DVT, this benefit was apparent over 24 months post-treatment. 10 
 11 
Take Home Message: Patients with iliofemoral DVT have a worse long-term prognosis (poorer QOL) 12 
than patients with femoral-popliteal DVT.  Early use of pharmacomechanical catheter-directed 13 
thrombolysis improves QOL in patients with acute iliofemoral DVT and may be reasonable to consider 14 
in selected patients who have severe symptoms, low bleeding risk, and a willingness to undergo a 15 
catheter-based procedure, after careful discussion of the benefits and risks. 16 
 17 
Table of Contents Summary 18 
In the ATTRACT randomized trial, among patients with proximal DVT, early use of 19 
pharmacomechanical catheter-directed thrombolysis had a beneficial effect on QOL during the 20 
first 6 months post-treatment. In proximal DVT patients with iliofemoral DVT, this QOL benefit 21 
was apparent over 24 months post-treatment.  22 
  23 
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Abstract  1 
Background: After deep vein thrombosis (DVT), many patients have impaired quality of life 2 
(QOL). We aimed to assess if pharmacomechanical catheter-directed thrombolysis (PCDT) 3 
improves short-term or long-term QOL in patients with proximal DVT and if QOL is related to 4 
extent of DVT. 5 
Methods: The ATTRACT Trial was an assessor-blinded randomized trial that compared PCDT 6 
with no PCDT in patients with DVT of the femoral, common femoral, or iliac veins. QOL was 7 
assessed at baseline and 1, 6, 12, 18 and 24 months using the VEINES-QOL/Sym disease-8 
specific QOL measure and the SF-36 (PCS and MCS summary scores) general QOL measures. 9 
Change in QOL scores from baseline to assessment time were compared in the PCDT and No 10 
PCDT treatment groups overall, and in the iliofemoral DVT and femoral-popliteal DVT 11 
subgroups.  12 
Results: 691 of 692 ATTRACT patients were analysed (mean age 53 years, 62% male, 57% 13 
iliofemoral DVT). VEINES-QOL change scores were greater (i.e. better) in PCDT vs. No PCDT 14 
from baseline to one month (difference 5.7; P=0.0006) and baseline to 6 months (5.1; P=0.0029), 15 
but not for other intervals. SF-36 PCS change scores were greater in PCDT vs. No PCDT from 16 
baseline to one month (difference 2.4; P=0.01), but not for other intervals.  Among iliofemoral 17 
DVT patients, VEINES-QOL change scores from baseline to all assessments were greater in the 18 
PCDT vs. No PCDT group; this was statistically significant in the intention-to-treat analysis at 1 19 
month (difference 10.0; P<0.0001) and 6 months (8.8; P<0.0001) and in the per-protocol analysis 20 
at 18 months (difference 5.8; P=0.0086) and 24 months (difference 6.6; P=0.0067). SF-36 PCS 21 
change scores were greater in PCDT vs. No PCDT from baseline to one month (difference 3.2; 22 
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P=0.0010), but not for other intervals. In contrast, in femoral-popliteal DVT patients, change 1 
scores from baseline to all assessments were similar in the PCDT and No PCDT groups. 2 
Conclusions: Among patients with proximal DVT, PCDT leads to greater improvement in 3 
disease-specific QOL than No PCDT at 1 month and 6 months, but not later. In patients with 4 
iliofemoral DVT, PCDT led to greater improvement in disease-specific QOL over 24 months. 5 
Clinical Trial Registration:  www.clinicaltrials.gov; NCT00790335 6 
Keywords:  deep vein thrombosis, quality of life, randomized trial, proximal DVT, catheter-7 
directed thrombolysis, iliofemoral DVT, femoral-popliteal DVT 8 
 9 
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INTRODUCTION  1 
 Despite treatment with anticoagulation and compression stockings, 30-50% of patients 2 
with proximal deep vein thrombosis (DVT) develop the post-thrombotic syndrome (PTS), a 3 
chronic, burdensome complication.1, 2 PTS is characterised by limb pain, heaviness, swelling and 4 
skin changes, including, in severe cases, venous ulceration. Greater recognition of PTS, with an 5 
increased focus on using patient reported outcome measures to assess the impact of illness, has 6 
highlighted the importance of studying health-related quality of life (QOL) in patients with DVT. 7 
 QOL is impaired in the acute phase of DVT3, 4, and development of PTS reduces QOL in 8 
the months to years following DVT.5 In the Acute Venous Thrombosis: Thrombus Removal with 9 
Adjunctive Catheter-Directed Thrombolysis (ATTRACT) Trial, we showed that 10 
pharmacomechanical catheter-directed thrombolysis (PCDT) did not reduce the occurrence of 11 
PTS during 24 months follow-up but reduced the severity of PTS and accelerated resolution of 12 
acute symptoms.6 In the current analysis, we assessed the effect of PCDT on short-term and 13 
long-term QOL in all patients in ATTRACT and in predefined subgroups with (iliofemoral 14 
DVT) or without (femoral-popliteal DVT) involvement of the iliac or common femoral vein, and 15 
assessed if this effect differed over time.  16 
 17 
METHODS 18 
 The ATTRACT Trial was an NHLBI (NIH)-sponsored, randomized controlled trial 19 
conducted at 56 U.S. clinical centers.6, 7 Patients with symptomatic proximal DVT of the 20 
femoral, common femoral, or iliac vein were potentially eligible. Patients were excluded if they 21 
were younger than 16 or older than 75 years; were pregnant; or had symptoms for more than 14 22 
days, high bleeding risk, active cancer, established PTS, or ipsilateral DVT in the prior 2 years. 23 
11 
 
 Patients were randomly assigned to receive PCDT (PCDT group) or not receive PCDT 1 
(No PCDT group). Randomization was stratified by clinical center and by whether there was 2 
involvement of the common femoral or iliac vein (“iliofemoral DVT”), or not (“femoral-3 
popliteal DVT”), as per societal reporting guidelines 8, 9. Patients in both treatment groups 4 
received initial and long-term anticoagulation as recommended in published guidelines10, 11, and 5 
were provided with knee-high, 30-40 mmHg elastic compression stockings (initially at the 10-6 
day follow-up visit, with replacement every 6 months).  The stockings were sized-to-fit and their 7 
daily use was encouraged by study personnel at each follow-up visit throughout the 24 months. 8 
PCDT was performed consistent with published guidelines.12  9 
Patients were assessed at baseline and 1 month (±7 days), 6 months (±1 month), 12 10 
months (±1 month), 18 months (±1 month), and 24 months (±2 months) post-randomization. 11 
PTS, the primary outcome of the ATTRACT Trial, was defined as a Villalta score of 5 or higher 12 
or an ulcer in the leg with the index DVT, any time between 6 and 24 months.13, 14 Full eligibility 13 
criteria, study investigators, study sites and detailed description of PCDT methods are provided 14 
in the primary publication.6 The study was approved by the institutional review boards at all 15 
participating centers, and all patients provided informed consent.  16 
Quality of life assessments 17 
Validated, self-administered instruments were used to measure venous disease-specific 18 
and general QOL. Venous disease-specific QOL was measured using the Venous Insufficiency 19 
Epidemiological and Economic Study Quality of Life (VEINES-QOL/Sym), a patient self-20 
assessment questionnaire.15 The instrument consists of 25 items that measure venous symptoms 21 
(heavy legs, aching legs, swelling, night cramps, heat or burning sensation, restless legs, 22 
throbbing, itching, tingling, intensity of leg pain), limitations in daily activities due to venous 23 
12 
 
disease, psychological impact of venous disease, and change over the past year. Responses are 1 
rated on 2-point to 7-point Likert scales of intensity, frequency, or agreement. The VEINES/Sym 2 
is a validated subscale of the VEINES instrument (10 of the 25 items) that measures venous 3 
symptoms. The VEINES-QOL/Sym has undergone comprehensive and rigorous psychometric 4 
evaluation and is acceptable, reliable, valid, and responsive for use as a patient-reported measure 5 
of outcome in studies of chronic venous disease, including PTS and DVT.15, 16 General QOL was 6 
measured using the Medical Outcomes Study Short-Form Health Survey-36, Version 2 (SF-7 
36v2), a validated, widely-used instrument.17, 18 The SF-36 has been used in other DVT studies 8 
to assess general QOL.5, 19-21 For all measures, lower scores indicate poorer QOL.  9 
Administration of QOL instruments 10 
The VEINES-QOL/Sym and SF-36 were combined into a single questionnaire document 11 
that took approximately 15-20 minutes for most patients to complete. Following a standard 12 
orientation, the patient filled in the questionnaire in a quiet office. The research nurse then 13 
checked for missing data and, without coercion, encouraged the patient to respond to all items. 14 
The nurse administering the questionnaire was blinded to the patient’s treatment allocation.  15 
Scoring of QOL instruments 16 
For the SF-36, an established computer scoring algorithm 22, 23 was used to generate 17 
summary scores for the Physical (PCS) and Mental (MCS) Component Scales (which reflect 18 
physical and mental health status, respectively). For VEINES-QOL, the intrinsic scoring method 19 
recently proposed by Bland24 was used, as the original “relative” scoring method15 has the 20 
disadvantage of always producing the same mean and standard deviation and, thus, cannot be 21 
used to study changes over time and to compare findings in different studies. Summary scores 22 
were computed for VEINES-QOL (impact of venous disease on QOL) and VEINES-Sym 23 
13 
 
(venous symptom severity).  1 
For SF-36 PCS and MCS, a change of 4 points is considered a minimal clinically 2 
important difference.25 For VEINES-QOL and VEINES-Sym scored using the intrinsic method, 3 
the minimal clinically important difference is uncertain, but is thought to be about 4 to 6 points, 4 
which is similar or a bit larger than for the original relative scoring method16. 5 
Sample size and power 6 
 The total sample size required for the ATTRACT Trial’s primary outcome of PTS was 7 
692 patients.6 For secondary outcomes including QOL scores, this sample size provided 8 
approximately 88% power to detect an effect size of 0.25 with continuous outcomes. An effect 9 
size of 0.25 translates into ability to detect a difference between groups of 1.25 points in the 10 
VEINES-QOL and VEINES-Sym and 2.5 points in the SF-36 PCS and MCS.  11 
Statistical analysis 12 
QOL analyses were performed using both modified intention-to-treat (ITT) and per-13 
protocol analysis sets. The modified ITT analysis set consisted of all patients randomized except 14 
for those who did not have DVT at enrollment. The per-protocol analysis set excluded 15 
randomized patients who, within 7 days post-randomization, were assigned to receive PCDT but 16 
did not undergo the procedure, or who were assigned to No PCDT but underwent PCDT.  17 
Group means and standard errors of the VEINES-QOL, VEINES-Sym, SF-36 PCS and 18 
MCS scores, and the mean differences and 95% confidence intervals (CIs) between treatment 19 
arms at each assessment were calculated. The repeated QOL scores over time (i.e. at baseline, 1, 20 
6, 12, 18, 24 months) were analyzed with growth curve mixed models using piecewise-linear 21 
regression.26 The models took into account the correlation between the repeated observations. 22 
Models included both fixed effects: the pre-specified baseline factors (treatment, center, extent of 23 
14 
 
DVT, sex), and continuous covariates (age at randomization, body mass index [BMI], and 1 
Villalta score); and random effects (actual visit dates, patient). Interaction terms (treatment x 2 
time for each visit) were assessed in each model, and a best-fit model was determined by 3 
removing non-significant (p>0.05) interaction terms. Change in QOL scores from baseline to 24 4 
months, the pre-specified primary QOL outcome, were compared between treatment arms using 5 
estimates derived from the final growth curve models.  6 
Sensitivity analyses for the VEINES (QOL and Sym) and SF-36 (PCS and MCS) 7 
outcomes used multiple imputation for missing baseline covariates and missing summary scores 8 
(except for deceased subjects), and the modelling structure described above. Missing data were 9 
assumed to be missing-at-random. The following auxiliary variables assisted in the imputation 10 
phase: for VEINES QOL/Sym scores, age, sex, BMI, extent of DVT and all available VEINES-11 
QOL/Sym scores from previous visits; and for SF-36 MCS/PCS scores, age, sex, race, BMI, and 12 
all available SF-36 scores from previous visits. Imputation was performed separately within each 13 
treatment arm. 14 
Analyses for the change scores, similar to the above, were reported for the iliofemoral 15 
DVT and femoral-popliteal DVT subgroups. The growth curve mixed models were expanded to 16 
assess the treatment x time interactions within the extent of DVT subgroups (i.e. treatment x time 17 
x extent) using the data from all patients. Plots of the response trajectories (from baseline to 24 18 
months) of the model-fitted VEINES-QOL change scores within each of the four groups defined 19 
by treatment (PCDT, No PCDT) and highest extent of DVT (iliofemoral, femoral-popliteal) were 20 
developed using locally-weighted scatterplot smoothing (LOESS), a non-parametric smoothing 21 
technique.27  22 
Finally, forest plots were created to display model-fitted baseline-to-24-month change 23 
15 
 
scores for PCDT vs. No PCDT within pre-specified subgroups defined by baseline age (<65, 1 
≥65), sex, race (white, non-white), BMI (<25, 25-29, ≥30), DVT symptom duration pre-2 
enrolment (<1 week, ≥1 week), DVT extent, and Villalta severity score (<5 points, 5-9, 10-14, 3 
≥15). Linear regression models for the change scores were used to assess differential treatment 4 
effects within subgroups (i.e. subgroup x treatment interactions). Change scores using the 5 
growth-curve model-fitted estimates (with and without multiple imputation) were analyzed 6 
separately.  7 
To account for the multiplicity of comparisons between treatment arms, statistical 8 
significance was declared only when P-values were less than 0.01. Statistical analyses were 9 
performed using SAS version 9.4 and the R version 3.5 programming language. 10 
 11 
RESULTS 12 
Between December 2009 and December 2014, 692 patients were randomized (337 to 13 
PCDT, 355 to No PCDT) and were followed for 2 years (Figure 1). One patient assigned to the 14 
PCDT group was found not to have a qualifying DVT and, therefore, was excluded from all 15 
analyses, leaving 691 patients in the modified ITT analysis set. Within 7 days of randomization, 16 
a further 11 patients who were assigned to receive PCDT but did not have PCDT, and 5 patients 17 
who were assigned to No PCDT but had PCDT were excluded from the per-protocol analysis 18 
(675 patients in per-protocol analysis set).  19 
Baseline characteristics of the patients were similar in the PCDT and No PCDT groups 20 
(Table 1). Overall, median age was 53 years, 62% of patients were male, 78% were white, and 21 
median BMI was 31 kg/m2.  The qualifying DVT was iliofemoral in 57% of patients and 22 
femoral-popliteal in 43% of patients.  23 
16 
 
Quality of life 1 
Detailed summaries of the raw QOL scores over time are presented in the Supplement 2 
(Tables A-I). The numbers of patients who completed QOL assessments at each visit are shown 3 
in Table J. In this section, we provide results for the change in QOL scores from baseline to each 4 
assessment time. 5 
All Patients 6 
In the modified ITT analysis set, model-fitted VEINES-QOL change scores from baseline 7 
to 24 months (primary outcome) was an average of 3.9 points higher in PCDT than No PCDT 8 
patients (P=0.04; Table 2). Difference in change scores in favor of PCDT achieved statistical 9 
significance at 1 month (5.7; P=0.0006) and at 6 months (5.1; P=0.0029), but not at 12 months 10 
and at 18 months (Table 2). 11 
For the VEINES symptom subscale (VEINES-Sym), there was a suggestion that the 12 
model-fitted change scores were greater in PCDT vs. No PCDT from baseline to 6 months 13 
(difference 4.3; P=0.045) but not at any other change interval (Table 2). 14 
For SF-36 PCS, the model-fitted change score was greater in PCDT than No PCDT 15 
patients at 1 month (difference 2.4; P=0.012) but not at any other change interval. For SF-36 16 
MCS, there were no differences between PCDT and No PCDT in model-fitted change scores at 17 
any assessment (Table 2). 18 
Results were similar in sensitivity analyses with models using multiple imputation 19 
(Tables 2), and when analyzed using the per-protocol analysis set (Supplement; Tables D and E).  20 
Subgroup Analysis 21 
Forest plots of differences in model-fitted baseline-to-24-month VEINES-QOL change 22 
scores between PCDT and No PCDT patients according to subgroups are shown in Figure 2. For 23 
17 
 
the change in QOL scores (VEINES-QOL, VEINES-Sym, SF-36 MCS, SF-36 PCS) from 1 
baseline to 24 months, none of the pre-specified subgroups, including for the iliofemoral vs. 2 
femoral-popliteal subgroups, showed statistically different (p<0.05) treatment effects. As a 3 
sensitivity analysis, we repeated the subgroup analysis using the change scores calculated from 4 
the raw data and the imputation-enhanced model-fitted estimates; none of these data sets showed 5 
any statistically significant subgroup effects.  6 
Iliofemoral DVT Subgroup 7 
In the modified ITT analysis set, model-fitted VEINES-QOL change scores from baseline 8 
to all assessment times were greater in the PCDT group. Compared to the differences at 1 month 9 
(difference 10.0; P<0.0001) and at 6 months (difference 8.8; P<0.0001), the differences in favor 10 
of PCDT were about half as large at 12 months (difference 4.3; P=0.046), 18 months (difference 11 
4.9; P=0.024), and at 24 months (difference 5.5; P=0.023). For VEINES-Sym, results were 12 
similar to those of VEINES-QOL (Table 3).  13 
For SF-36 PCS, model-fitted change scores at 1 month were greater in the PCDT group 14 
(difference 3.2; P=0.0010), but change scores from baseline to other assessment times, including 15 
24 months, did not differ (Table 3). For SF-36 MCS, there were no differences between PCDT 16 
and No PCDT in model-fitted change in scores from baseline to any assessment, including 24 17 
months (Table 3). 18 
Results were substantively similar in the sensitivity analyses with models using multiple 19 
imputation (Tables 3). When analyzed using the per-protocol analysis set (Supplement; Tables F 20 
and G), the above noted differences between PCDT and no PCDT were greater, particularly for 21 
change in VEINES-QOL scores from baseline to 18 months (difference 5.8; P=0.0086) and 22 
baseline to 24 months (difference 6.6; P=0.0067) (Table F).  23 
18 
 
Femoral-popliteal DVT Subgroup 1 
 VEINES-QOL, VEINES-Sym, SF-36 PCS and SF-36 MCS change scores from baseline 2 
to each assessment were similar in the PCDT and No PCDT groups (Table 4). Results were 3 
similar in sensitivity analyses with models using multiple imputation and when analyzed using 4 
the per-protocol analysis set (Supplement; Tables H and I).  5 
Trajectories of the VEINES-QOL scores in Iliofemoral and Femoral-popliteal DVT Subgroups 6 
Figure 3 shows LOESS-smoothed estimates of the model predicted VEINES-QOL 7 
change scores from baseline to each assessment in the four groups defined by treatment (PCDT, 8 
No PCDT) and extent of DVT (iliofemoral, femoral-popliteal). All groups showed substantial 9 
improvement in VEINES-QOL change scores during follow-up. The change in the PCDT 10 
iliofemoral subgroup was greater than in the No PCDT iliofemoral subgroup, particularly during 11 
the first 6 months. The change in PCDT and No PCDT femoral-popliteal groups were similar at 12 
all time points.  13 
Interpretation of the growth curve model QOL results 14 
In addition to evaluating QOL improvement with PCDT from baseline to individual 15 
timepoints through 2 years, our analysis sought to determine the pattern of change over time.  16 
With the inclusion of the extent of DVT subgroups in the growth curve model, we observed that 17 
the improvement in VEINES-QOL/Sym and SF-36 PCS QOL with PCDT was statistically 18 
significantly greater in the iliofemoral DVT group compared with the femoral-popliteal DVT 19 
group during the first month post-randomization, but not during the intervals from 1 to 6 months, 20 
6 to 12 months, 12 to 18 months, or 18 to 24 months (Supplement, Appendix A). The 21 
incremental changes in VEINES-QOL scores between assessments are shown in Figure 4. For all 22 
19 
 
four groups, there are substantial QOL incremental improvements from baseline to 1 month, and 1 
from 1 month to 6 months, but not beyond that. For patients with iliofemoral DVT, the largest 2 
interval improvement occurs in PCDT vs. No PCDT patients from baseline to 1 month. 3 
However, for the between-visit intervals beyond 1 month, differences in the degree of QOL 4 
change between treatment arms are not apparent. For femoral-popliteal DVT patients, the 5 
treatment differences were negligible for all incremental changes. 6 
 7 
DISCUSSION 8 
In our original publication describing the main results of the ATTRACT Trial, we 9 
evaluated QOL scores at two time-points (baseline and 24 months post-randomization) in the 10 
overall study population, and reported no difference in the degree of change in QOL between 11 
patients who were assigned, versus not assigned, to PCDT.  In the current, more detailed analysis 12 
of QOL outcomes in the ATTRACT Trial, we used more sophisticated analytic methods that 13 
allowed us to more fully utilize all available data from all follow-up assessments, enabling us to 14 
assess time-dependent patterns of QOL change during different time periods within the 24 15 
months of study follow-up.    16 
We report four main findings. First, regardless of treatment group, venous disease-17 
specific QOL and general QOL improved markedly during the 24 months after diagnosis of 18 
proximal DVT, with most of this improvement occurring during the first 6 months after 19 
diagnosis. Second, patients with iliofemoral DVT had poorer QOL scores over the 24 months of 20 
follow-up than patients with femoral-popliteal DVT. Third, in the total study population, patients 21 
in the PCDT group had greater improvement in venous disease-specific QOL during the first 1 22 
month and 6 months after randomization compared with the No PCDT group, but this benefit 23 
20 
 
was no longer apparent by 12, 18 or 24 months, and there was no difference in the extent of 1 
improvement with PCDT in overall physical or mental general QOL at any time point. Fourth, 2 
the greater improvement in disease-specific QOL with PCDT during the first 6 months was only 3 
observed in patients who had iliofemoral DVT, and not in patients with femoral-popliteal DVT. 4 
Our results also suggest that in patients with iliofemoral DVT, but not those with femoral-5 
popliteal DVT, disease-specific QOL change scores were also better with PCDT at 12, 18, and 6 
24 months. In patients with iliofemoral DVT, the improvement in disease-specific QOL with 7 
PCDT vs. No PCDT was large enough to be considered clinically important during the first 6 8 
months, but of uncertain clinical importance subsequently.  9 
Our observation that general and venous disease-specific QOL improves over 24 months 10 
after DVT and that most of this improvement occurs in the first 6 months after DVT is consistent 11 
with previous reports by our group5, 21 and by the CAVENT (Catheter-Directed Venous 12 
Thrombolysis in Acute Iliofemoral Vein Thrombosis) trial investigators 28.  13 
 We found that patients with iliofemoral DVT have worse QOL than patients with 14 
femoral-popliteal DVT, which is consistent with previous observations that QOL is poorer after 15 
proximal DVT than after isolated distal DVT 5, and that PTS is more common and more severe 16 
after iliofemoral DVT than after femoral-popliteal or more distal DVT.29, 30  17 
Why might PCDT have improved venous QOL even though it did not prevent PTS? First, 18 
most of the improvement in QOL was in the first 6 months and the ATTRACT trial did find that 19 
PCDT reduced clot burden and reduced early leg pain and swelling to a greater extent than No 20 
PCDT, and was associated with a reduced point prevalence of PTS at the 6-month visit (but not 21 
thereafter)6. Second, although PCDT did not prevent PTS it did reduce its severity, and less 22 
severe PTS is likely to be associated with improved QOL. Third, although both measures ask 23 
21 
 
about leg pain, heaviness, cramping, itching, and pins and needles sensation, the VEINES-QOL 1 
instrument used to measure venous QOL may have captured different clinical characteristics than 2 
the Villalta scale used to measure PTS.  We did not utilize a self-reported QOL measure as the 3 
study’s primary outcome because of the possibility of response bias that could stem from 4 
patients’ knowledge of their treatment allocation in this open-label study.  Further work to 5 
compare the performance and correlation of these and other outcome measures would be of 6 
interest.   7 
 Strengths of our study include that we assessed both disease-specific and general QOL 8 
repeatedly during 24 months using validated measures. Although patients and healthcare 9 
providers were not blinded to treatment, bias was minimized by having central randomization, 10 
allocation concealment, blinded outcome assessment, and comparable use of anticoagulants and 11 
compression stockings during follow-up in both groups. Our modelling techniques enabled us to 12 
use all of the data during follow-up, to assess if effects on QOL differed over time, and to adjust 13 
for baseline factors that may influence QOL. Consistency of findings in sensitivity analysis that 14 
used multiple imputation to address missing data and in per-protocol analyses increase 15 
confidence in the validity of our findings. Stratification of randomization by whether the 16 
iliofemoral outflow tract was involved, which is known to influence the risk of PTS and its 17 
severity, supports separate reporting of findings in the iliofemoral and femoral-popliteal 18 
subgroups, as recommended by societal consensus guidelines.8, 9 19 
 Our study also has limitations. During the ATTRACT Trial, a number of measures were 20 
taken to ensure that patients attended follow-up visits, including electronic reminders to study 21 
sites of upcoming patient visits, and routine education of study teams on best practices for patient 22 
retention at investigator meetings, teleconferences, and via electronic communications. In some 23 
22 
 
instances, patients who had moved out of town were permitted to be seen at different study sites.   1 
Nevertheless, we had missing QOL responses primarily due to missed visits, which increased 2 
over time and were greater in the No PCDT group, for reasons that are unclear. However, as 3 
noted in the preceding paragraph, sensitivity analyses suggest that our findings are robust. We 4 
also acknowledge that our analysis has limited power to detect differences in treatment effects 5 
between subgroups and, particularly, within each of the femoral-popliteal and iliofemoral 6 
subgroups.     7 
 In conclusion, PCDT leads to better disease-specific QOL at 1 month and 6 months in 8 
patients with iliofemoral DVT, but not in patients with femoral-popliteal DVT. PCDT also 9 
appears to lead to greater improvement in disease-specific QOL over 24 months in patients with 10 






Table 1. Demographic and Clinical Characteristics at Baseline 1 
 
PCDT No PCDT Total 
n = 336 n = 355 N = 691 
Age, years: median (IQR)  52 (41, 62) 53 (43, 62)  53 (42, 62) 
Male: n (%)  205 (61)  221 (62)  426 (62) 
Race: n (%)    
White  265 (79)  276 (78)  541 (78) 
Black/African-American  61 (18)  62 (17)  123 (18) 
Other  10 (3)  17 (5)       27 (31) 
Weight, kg: median (IQR) 95 (81, 111) 92 (79, 110) 93 (80, 110) 
Body mass index, kg/m2: median (IQR) 31 (27, 36) 30 (26, 35) 31 (27, 35) 
DVT characteristics: n (%)    
Left leg with index DVT   207 (62)  218 (61)  425 (62) 
Extends into common femoral and/or iliac vein  195 (58)  196 (55)  391 (57) 
Previous DVT or PE  83 (25)  87 (25)  170 (25) 
Previous ipsilateral DVT  5 (1) 14 (4)  19 (3) 
DVT risk factors: n (%)*    
Major surgery  27 (8)  34 (10)  61 (9) 
Hospitalization  26 (8)  38 (11)  64 (9) 
Plaster cast immobilization  8 (2)  9 (3)  17 (2) 
Childbirth  3 (1)  5 (1)  8 (1) 
Outpatient when DVT diagnosed: n (%)  268 (80)  300 (85)  568 (82) 
DVT symptom duration (prior to randomization), 
days: median (IQR)  6 (4, 10) 6 (4, 9) 6  (4, 10) 
 * Patients may contribute to more than one category 2 
IQR, inter-quartile range; DVT, deep vein thrombosis; PE, pulmonary embolism 3 
 4 
 5 
  6 
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Notes for Tables 2-4 1 
* statistical comparison using an unpaired t-test (based on the raw data) 2 
† statistical comparison using a Wald test using a growth curve model with piece-wise linear regression 3 
over time adjusted for stratification factors: extent of DVT (iliofemoral vs. femoral-popliteal) and 4 
center, and baseline covariates: age, sex, BMI, Villalta score. 5 
VEINES-QOL score (0-100 range) – higher is better; SF-36 major scales (0-100 range): physical 6 
component score (PCS) and mental component score (MCS) – higher is better; a 4-point difference is 7 
considered to be clinically meaningful 8 
‡ Auxiliary variables used in multiple imputation (MI): for SF-36 (MCS and PCS), age (continuous), sex, 9 
race, BMI (continuous) and all available SF-36 scores from previous visits; for VEINES-QOL, age 10 
(continuous), sex, BMI, extent of index DVT and all available VEINES scores from previous visits  11 
 12 
SE, standard error; Est, estimate; 95% CI, 95% confidence interval 13 
 14 




Table 2. All Patients: Change in Disease-specific and General QOL according to Treatment 
Outcome Measure 
PCDT No PCDT PCDT – No PCDT Difference 
n Mean SE n Mean SE Est. SE 95% CI p 
VEINES-QOL:            
Baseline to 1 month:            
Raw data* 314 14.2 1.4 314 8.5 1.2 5.7 1.8 2.1 9.3 0.0021 
Model fitted†  14.7 1.3  9.0 1.3 5.7 1.7 2.5 9.0 0.0006 
Model fitted using MI‡  14.9 1.3  8.9 1.3 6.0 1.7 2.7 9.3 0.0003 
Baseline to 6 months:            
Raw data* 287 26.0 1.6 277 21.3 1.5 4.7 2.1 0.5 8.9 0.03 
Model fitted†  26.5 1.3  21.5 1.3 5.1 1.7 1.7 8.4 0.0029 
Model fitted using MI‡  27.1 1.3  21.6 1.3 5.5 1.6 2.3 8.7 0.0008 
Baseline to 12 months:            
Raw data* 267 26.0 1.6 252 25.1 1.6 0.9 2.2 -3.5 5.3 0.70 
Model fitted†  26.8 1.3  25.3 1.4 1.5 1.7 -1.8 4.8 0.38 
Model fitted using MI‡  27.2 1.3  25.7 1.3 1.5 1.7 -1.8 4.7 0.37 
Baseline to 18 months:            
Raw data* 244 27.2 1.8 220 25.5 1.7 1.7 2.5 -3.1 6.6 0.48 
Model fitted†  27.4 1.3  24.7 1.3 2.7 1.7 -0.6 5.9 0.11 
Model fitted using MI‡  28.1 1.3  25.3 1.3 2.7 1.6 -0.5 5.9 0.10 
Baseline to 24 months:            
Raw data* 249 27.4 1.7 227 24.1 1.8 3.3 2.5 -1.6 8.2 0.18 
Model fitted†  28.1 1.5  24.2 1.5 3.9 1.9 0.1 7.6 0.04 
Model fitted using MI‡  28.9 1.6  25.0 1.5 3.9 2.0 0.1 7.8 0.04 
VEINES-Sym:            
Baseline to 1 month:            
Raw data* 311 12.1 1.5 314 8.8 1.3 3.3 2.0 -0.6 7.1 0.10 
Model fitted†  12.9 1.5  9.6 1.5 3.3 2.1 -0.8 7.4 0.11 
Model fitted using MI‡  13.1 1.5  9.3 1.5 3.8 2.1 -0.4 8.0 0.08 
Baseline to 6 months:            
Raw data* 285 20.2 1.6 277 16.2 1.5 4.0 2.2 -0.3 8.3 0.07 
Model fitted†  21.1 1.5  16.8 1.5 4.3 2.1 0.1 8.4 0.04 
Model fitted using MI‡  21.5 1.5  16.8 1.5 4.7 2.2 0.4 9.1 0.03 
Baseline to 12 months:            
Raw data* 266 18.1 1.6 252 18.1 1.6 0.0 2.3 -4.5 4.5 0.99 
Model fitted†  19.1 1.5  18.2 1.5 0.9 2.1 -3.3 5.1 0.68 
Model fitted using MI‡  19.2 1.5  18.4 1.5 0.8 2.2 -3.5 5.1 0.72 
Baseline to 18 months:            
Raw data* 243 19.3 1.8 220 18.1 1.8 1.2 2.6 -3.9 6.2 0.65 
Model fitted†  20.2 1.5  18.2 1.5 2.0 2.1 -2.2 6.1 0.35 
Model fitted using MI‡  20.6 1.5  18.7 1.5 2.0 2.1 -2.1 6.1 0.34 
Baseline to 24 months:            
Raw data* 248 20.7 1.7 227 18.2 1.7 2.5 2.4 -2.2 7.1 0.30 
Model fitted†  21.2 1.6  18.2 1.7 3.0 2.3 -1.5 7.6 0.19 




Table 2. All Patients: Change in Disease-specific and General QOL according to Treatment 
Outcome Measure 
PCDT No PCDT PCDT – No PCDT Difference 
n Mean SE n Mean SE Est. SE 95% CI p 
SF-36 PCS:             
Baseline to 1 month:             
Raw data* 313 7.2 0.6 314 4.9 0.6 2.3 0.9 0.6 4.0 0.0077 
Model fitted†  7.4 0.7  5.1 0.7 2.4 0.9 0.5 4.2 0.01 
Model fitted using MI‡  7.6 0.7  5.0 0.7 2.6 1.0 0.7 4.4 0.0072 
Baseline to 6 months:            
Raw data* 287 10.9 0.8 277 9.5 0.7 1.4 1.1 -0.7 3.5 0.19 
Model fitted†  11.5 0.7  9.7 0.7 1.8 0.9 0.0 3.6 0.05 
Model fitted using MI‡  11.8 0.7  9.6 0.7 2.2 1.0 0.3 4.1 0.02 
Baseline to 12 months:            
Raw data* 266 11.6 0.8 252 10.4 0.8 1.2 1.1 -1.0 3.4 0.27 
Model fitted†  11.5 0.7  10.0 0.7 1.5 0.9 -0.3 3.4 0.10 
Model fitted using MI‡  11.8 0.7  10.0 0.7 1.8 0.9 -0.1 3.6 0.06 
Baseline to 18 months:            
Raw data* 242 11.9 0.8 220 11.6 0.9 0.3 1.2 -2.1 2.6 0.83 
Model fitted†  11.6 0.7  10.3 0.7 1.3 1.0 -0.7 3.3 0.21 
Model fitted using MI‡  11.9 0.7  10.5 0.7 1.3 1.0 -0.6 3.3 0.18 
Baseline to 24 months:            
Raw data* 248 11.7 0.9 227 11.0 0.9 0.6 1.2 -1.8 3.0 0.62 
Model fitted†  11.7 0.8  10.7 0.8 1.0 1.1 -1.2 3.3 0.37 
Model fitted using MI‡  11.9 0.8  11.0 0.8 0.9 1.1 -1.3 3.1 0.42 
SF-36 MCS:            
Baseline to 1 month:            
Raw data* 314 -0.2 0.7 314 -0.5 0.6 0.3 0.9 -1.5 2.2 0.71 
Model fitted†  0.3 0.1  0.4 0.1 -0.1 0.1 -0.3 0.1 0.42 
Model fitted using MI‡  0.3 0.1  0.5 0.1 -0.2 0.1 -0.4 0.0 0.11 
Baseline to 6 months:            
Raw data* 287 1.8 0.7 277 1.6 0.8 0.2 1.1 -1.9 2.2 0.88 
Model fitted†  1.8 0.5  2.4 0.5 -0.6 0.7 -1.9 0.8 0.42 
Model fitted using MI‡  1.8 0.5  2.9 0.5 -1.1 0.7 -2.4 0.3 0.11 
Baseline to 12 months:            
Raw data* 267 1.8 0.8 252 1.7 0.8 0.1 1.1 -2.1 2.3 0.93 
Model fitted† . 2.2 0.4  2.8 0.5 -0.6 0.6 -1.7 0.5 0.30 
Model fitted using MI‡ . 2.3 0.5  3.3 0.5 -1.0 0.6 -2.1 0.1 0.08 
Baseline to 18 months:            
Raw data* 243 2.0 0.9 220 2.2 0.8 -0.2 1.2 -2.6 2.2 0.87 
Model fitted†  2.5 0.5  3.2 0.5 -0.6 0.6 -1.8 0.5 0.29 
Model fitted using MI‡  2.7 0.5  3.6 0.5 -1.0 0.6 -2.2 0.2 0.11 
Baseline to 24 months:            
Raw data* 249 2.9 0.8 227 3.0 0.8 -0.1 1.1 -2.3 2.1 0.94 
Model fitted†  2.9 0.6  3.6 0.6 -0.7 0.7 -2.1 0.8 0.36 




Table 3. Iliofemoral DVT Subgroup: Change in Disease-specific and General QOL according to 
Treatment 
Outcome Measure 
PCDT No PCDT PCDT – No PCDT Difference 
n Mean SE n Mean SE Est. SE 95% CI p 
VEINES-QOL:            
Baseline to 1 month:            
Raw data* 180 15.5 1.7 169 5.3 1.8 10.2 2.5 5.3 15.1 <0.0001 
Model fitted†  16.1 1.6  6.1 1.7 10.0 2.2 5.7 14.2 <0.0001 
Model fitted using MI‡  16.0 1.7  6.0 1.7 10.1 2.1 5.9 14.3 <0.0001 
Baseline to 6 months:            
Raw data* 168 27.1 2.0 144 18.4 2.1 8.7 2.9 2.9 14.5 0.0032 
Model fitted†  27.7 1.7  18.8 1.8 8.8 2.2 4.5 13.2 <0.0001 
Model fitted using MI‡  28.1 1.7  18.9 1.7 9.2 2.1 5.0 13.3 <0.0001 
Baseline to 12 months:            
Raw data* 153 26.8 2.2 133 24.4 2.2 2.4 3.1 -3.8 8.6 0.44 
Model fitted†  27.7 1.7  23.3 1.8 4.3 2.2 0.1 8.6 0.05 
Model fitted using MI‡  27.9 1.7  23.5 1.7 4.4 2.1 0.3 8.5 0.04 
Baseline to 18 months:            
Raw data* 139 28.3 2.4 122 25.8 2.4 2.4 3.4 -4.2 9.0 0.47 
Model fitted†  28.1 1.7  23.2 1.8 4.9 2.2 0.6 9.1 0.02 
Model fitted using MI‡  28.6 1.8  23.4 1.7 5.2 2.2 0.9 9.5 0.02 
Baseline to 24 months:            
Raw data* 141 28.3 2.3 128 23.3 2.6 5.0 3.4 -1.8 11.8 0.15 
Model fitted†  28.5 1.9  23.0 2.0 5.5 2.4 0.8 10.2 0.02 
Model fitted using MI‡  29.4 2.0  23.4 1.9 6.0 2.5 1.0 11.0 0.02 
VEINES-Sym:            
Baseline to 1 month:            
Raw data* 177 12.7 1.9 169 5.7 1.9 7.1 2.7 1.7 12.4 0.0094 
Model fitted†  13.6 1.7  6.6 1.8 7.1 2.2 2.7 11.4 0.0015 
Model fitted using MI‡  13.6 1.7  6.5 1.8 7.0 2.3 2.6 11.5 0.0020 
Baseline to 6 months:            
Raw data* 166 20.1 2.1 144 13.6 2.1 6.5 3.0 0.7 12.4 0.03 
Model fitted†  21.8 1.8  13.9 1.8 7.9 2.2 3.5 12.3 0.0004 
Model fitted using MI‡  22.0 1.8  14.2 1.9 7.9 2.3 3.3 12.5 0.0008 
Baseline to 12 months:            
Raw data* 152 18.2 2.2 133 17.1 2.3 1.1 3.2 -5.2 7.3 0.74 
Model fitted†  19.7 1.7  15.8 1.8 4.0 2.2 -0.3 8.3 0.07 
Model fitted using MI‡  19.7 1.7  16.1 1.9 3.7 2.3 -0.8 8.2 0.11 
Baseline to 18 months:            
Raw data* 138 20.2 2.4 122 18.3 2.5 1.9 3.5 -4.9 8.7 0.58 
Model fitted†  20.7 1.7  16.0 1.8 4.7 2.2 0.5 8.9 0.03 
Model fitted using MI‡  21.2 1.7  16.5 1.9 4.7 2.2 0.3 9.0 0.04 
Baseline to 24 months:            
Raw data* 140 20.8 2.2 128 17.2 2.4 3.6 3.3 -2.8 10.1 0.27 
Model fitted†  21.6 1.9  16.2 1.9 5.4 2.4 0.7 10.1 0.02 
Model fitted using MI‡  22.7 1.9  17.0 2.0 5.6 2.4 0.8 10.4 0.02 
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Table 3. Iliofemoral DVT Subgroup: Change in Disease-specific and General QOL according to 
Treatment 
Outcome Measure 
PCDT No PCDT PCDT – No PCDT Difference 
n Mean SE n Mean SE Est. SE 95% CI p 
SF-36 PCS:             
Baseline to 1 month:            
Raw data* 180 8.2 0.8 169 3.6 0.9 4.6 1.2 2.2 7.0 0.0002 
Model fitted†  7.7 0.8  4.5 0.8 3.2 1.0 1.3 5.1 0.0010 
Model fitted using MI‡  7.8 0.8  4.5 0.8 3.3 1.0 1.4 5.2 0.0007 
Baseline to 6 months:            
Raw data* 168 11.0 1.0 144 8.1 1.1 2.9 1.5 0.0 5.8 0.05 
Model fitted†  11.3 0.8  9.3 0.8 1.9 1.0 0.0 3.9 0.05 
Model fitted using MI‡  11.7 0.8  9.3 0.8 2.4 1.0 0.4 4.4 0.02 
Baseline to 12 months:            
Raw data* 153 11.4 1.1 133 10.4 1.2 1.0 1.6 -2.2 4.3 0.53 
Model fitted†  11.1 0.8  10.0 0.8 1.1 1.0 -0.8 3.0 0.25 
Model fitted using MI‡  11.5 0.8  10.1 0.8 1.4 0.9 -0.4 3.3 0.13 
Baseline to 18 months:            
Raw data* 138 11.5 1.2 122 11.9 1.3 -0.4 1.7 -3.8 2.9 0.81 
Model fitted†  11.0 0.8  10.7 0.9 0.3 1.0 -1.7 2.2 0.78 
Model fitted using MI‡  11.3 0.8  10.9 0.9 0.5 1.0 -1.5 2.4 0.64 
Baseline to 24 months:            
Raw data* 141 11.2 1.2 128 11.2 1.3 0.0 1.8 -3.5 3.4 0.99 
Model fitted† . 10.8 0.9  11.4 0.9 -0.5 1.1 -2.7 1.7 0.63 
Model fitted using MI‡ . 11.2 0.9  11.7 1.0 -0.5 1.1 -2.7 1.7 0.66 
SF-36 MCS:            
Baseline to 1 month:            
Raw data* 180 0.1 0.9 169 0.3 1.0 -0.1 1.3 -2.7 2.5 0.93 
Model fitted†  0.3 0.1  0.4 0.1 -0.1 0.1 -0.3 0.2 0.56 
Model fitted using MI‡  0.3 0.1  0.5 0.1 -0.2 0.1 -0.4 0.1 0.21 
Baseline to 6 months:            
Raw data* 168 1.9 0.9 144 3.1 1.1 -1.2 1.5 -4.0 1.7 0.43 
Model fitted†  1.8 0.6  2.2 0.6 -0.5 0.8 -2.0 1.1 0.56 
Model fitted using MI‡  1.8 0.6  2.8 0.6 -0.9 0.8 -2.4 0.5 0.21 
Baseline to 12 months:            
Raw data* 153 1.9 1.0 133 3.4 1.2 -1.5 1.6 -4.6 1.6 0.34 
Model fitted†  2.1 0.5  2.6 0.5 -0.5 0.7 -1.9 0.8 0.41 
Model fitted using MI‡  2.2 0.5  3.2 0.5 -0.9 0.6 -2.2 0.3 0.15 
Baseline to 18 months:            
Raw data* 138 1.5 1.2 122 3.4 1.2 -1.8 1.7 -5.2 1.5 0.27 
Model fitted†  2.4 0.5  3.1 0.5 -0.6 0.6 -1.9 0.6 0.33 
Model fitted using MI‡  2.6 0.5  3.5 0.5 -0.9 0.6 -2.2 0.3 0.16 
Baseline to 24 months:            
Raw data* 141 3.7 1.1 128 3.9 1.2 -0.2 1.6 -3.3 2.9 0.88 
Model fitted†  2.8 0.6  3.5 0.6 -0.7 0.7 -2.2 0.7 0.32 
Model fitted using MI‡  3.0 0.6  3.9 0.6 -0.9 0.7 -2.4 0.6 0.23 
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Table 4. Femoral-popliteal DVT Subgroup: Change in Disease-specific and General QOL according 
to Treatment  
Outcome Measure 
PCDT No PCDT PCDT – No PCDT Difference 
n Mean SE n Mean SE Est. SE 95% CI p 
VEINES-QOL:            
Baseline to 1 month:            
Raw data* 134 12.4 2.2 145 12.3 1.6 0.1 2.7 -5.2 5.4 0.97 
Model fitted†  13.0 1.9  12.5 1.8 0.5 2.4 -4.2 5.2 0.83 
Model fitted using MI‡  13.5 1.9  12.6 1.8 0.9 2.5 -3.9 5.7 0.71 
Baseline to 6 months:            
Raw data* 119 24.4 2.4 133 24.3 2.0 0.0 3.1 -6.1 6.1 0.75 
Model fitted†  25.0 1.9  24.4 1.9 0.6 2.4 -4.1 5.4 0.32 
Model fitted using MI‡  25.8 1.9  24.8 1.9 1.0 2.4 -3.6 5.7 0.28 
Baseline to 12 months:            
Raw data* 114 24.9 2.4 119 25.9 2.1 -1.0 3.2 -7.3 5.3 0.83 
Model fitted†  25.5 1.9  27.9 1.9 -2.4 2.4 -7.0 2.3 0.90 
Model fitted using MI‡  26.1 1.9  28.6 1.9 -2.5 2.3 -7.1 2.1 0.82 
Baseline to 18 months:            
Raw data* 105 25.8 2.7 98 25.0 2.5 0.8 3.7 -6.5 8.1 0.99 
Model fitted†  26.5 2.0  26.8 1.9 -0.3 2.4 -5.0 4.5 0.79 
Model fitted using MI‡  27.2 2.0  27.7 1.9 -0.6 2.4 -5.3 4.2 0.67 
Baseline to 24 months:            
Raw data* 108 26.3 2.6 99 25.2 2.3 1.1 3.5 -5.8 8.1 0.75 
Model fitted†  27.4 2.2  25.7 2.1 1.8 2.7 -3.5 7.1 0.51 
Model fitted using MI‡  28.3 2.2  26.9 2.2 1.4 2.8 -4.1 6.9 0.61 
VEINES-Sym:            
Baseline to 1 month:            
Raw data* 134 11.2 2.3 145 12.5 1.8 -1.3 2.9 -6.9 4.4 0.66 
Model fitted†  12.4 2.0  12.7 1.9 -0.3 2.5 -5.1 4.5 0.91 
Model fitted using MI‡  12.8 2.0  12.4 1.9 0.4 2.5 -4.5 5.4 0.86 
Baseline to 6 months:            
Raw data* 119 20.3 2.4 133 19.1 2.2 1.2 3.3 -5.2 7.7 0.70 
Model fitted†  20.8 2.0  19.6 1.9 1.1 2.4 -3.7 5.9 0.65 
Model fitted using MI‡  21.2 2.0  19.6 1.9 1.7 2.5 -3.2 6.6 0.50 
Baseline to 12 months:            
Raw data* 114 18.0 2.4 119 19.2 2.3 -1.2 3.3 -7.6 5.3 0.72 
Model fitted†  18.9 2.0  20.9 1.9 -2.1 2.4 -6.8 2.6 0.39 
Model fitted using MI‡  18.9 2.0  20.9 1.9 -2.1 2.3 -6.6 2.5 0.38 
Baseline to 18 months:            
Raw data* 105 18.0 2.8 98 17.9 2.7 0.1 3.8 -7.5 7.7 0.97 
Model fitted†  20.0 2.0  20.6 2.0 -0.7 2.4 -5.4 4.1 0.79 
Model fitted using MI‡  20.3 2.0  20.9 1.9 -0.6 2.3 -5.1 3.9 0.79 
Baseline to 24 months:            
Raw data* 108 20.4 2.7 99 19.5 2.1 0.9 3.5 -5.9 7.7 0.78 
Model fitted†  21.1 2.2  20.3 2.1 0.8 2.7 -4.5 6.1 0.78 
Model fitted using MI‡  21.7 2.1  20.8 2.1 0.9 2.6 -4.3 6.0 0.74 
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Table 4. Femoral-popliteal DVT Subgroup: Change in Disease-specific and General QOL according 
to Treatment  
Outcome Measure 
PCDT No PCDT PCDT – No PCDT Difference 
n Mean SE n Mean SE Est. SE 95% CI p 
SF-36 PCS:             
Baseline to 1 month:            
Raw data* 133 5.9 1.0 145 6.4 0.8 -0.5 1.2 -2.9 2.0 0.70 
Model fitted†  6.3 0.9  6.6 0.8 -0.3 1.1 -2.4 1.8 0.77 
Model fitted using MI‡  6.4 0.9  6.4 0.9 0.0 1.1 -2.2 2.1 0.97 
Baseline to 6 months:            
Raw data* 119 10.7 1.2 133 11.0 1.0 -0.3 1.5 -3.3 2.7 0.86 
Model fitted†  10.4 0.9  11.0 0.9 -0.6 1.1 -2.7 1.5 0.59 
Model fitted using MI‡  10.8 0.9  10.7 0.9 0.0 1.1 -2.1 2.1 0.98 
Baseline to 12 months:            
Raw data* 113 12.0 1.1 119 10.5 1.0 1.5 1.5 -1.4 4.5 0.31 
Model fitted†  10.9 0.9  11.0 0.9 -0.2 1.1 -2.2 1.9 0.88 
Model fitted using MI‡  11.1 0.9  10.9 0.8 0.2 1.0 -1.8 2.2 0.85 
Baseline to 18 months:            
Raw data* 104 12.4 1.2 98 11.2 1.2 1.2 1.7 -2.2 4.5 0.50 
Model fitted†  11.3 0.9  11.1 0.9 0.3 1.1 -1.9 2.5 0.82 
Model fitted using MI‡  11.5 0.9  11.1 0.9 0.4 1.1 -1.7 2.5 0.73 
Baseline to 24 months:            
Raw data* 107 12.3 1.2 99 10.9 1.2 1.4 1.7 -2.0 4.8 0.41 
Model fitted†  11.8 1.0  11.1 1.0 0.7 1.3 -1.8 3.2 0.59 
Model fitted using MI‡  11.8 1.0  11.3 1.0 0.5 1.2 -1.9 2.9 0.66 
SF-36 MCS:            
Baseline to 1 month:            
Raw data* 134 -0.6 1.0 145 -1.4 0.8 0.8 1.3 -1.7 3.4 0.53 
Model fitted†  0.3 0.1  0.4 0.1 -0.1 0.1 -0.3 0.2 0.56 
Model fitted using MI‡  0.3 0.1  0.5 0.1 -0.2 0.1 -0.4 0.1 0.21 
Baseline to 6 months:            
Raw data* 119 1.5 1.1 133 0.0 1.0 1.5 1.5 -1.5 4.6 0.33 
Model fitted†  1.8 0.6  2.2 0.6 -0.5 0.8 -2.0 1.1 0.56 
Model fitted using MI‡  1.8 0.6  2.8 0.6 -0.9 0.8 -2.4 0.5 0.21 
Baseline to 12 months:            
Raw data* 114 1.6 1.3 119 -0.2 1.0 1.9 1.6 -1.3 5.1 0.26 
Model fitted†  2.1 0.5  2.6 0.5 -0.5 0.7 -1.9 0.8 0.41 
Model fitted using MI‡  2.2 0.5  3.2 0.5 -0.9 0.6 -2.2 0.3 0.15 
Baseline to 18 months:            
Raw data* 105 2.6 1.2 98 0.7 1.1 1.9 1.7 -1.4 5.2 0.26 
Model fitted†  2.4 0.5  3.1 0.5 -0.6 0.6 -1.9 0.6 0.33 
Model fitted using MI‡  2.6 0.5  3.5 0.5 -0.9 0.6 -2.2 0.3 0.16 
Baseline to 24 months:            
Raw data* 108 1.8 1.1 99 1.8 1.2 0.1 1.6 -3.1 3.3 0.95 
Model fitted†  2.8 0.6  3.5 0.6 -0.7 0.7 -2.2 0.7 0.32 
Model fitted using MI‡  3.0 0.6  3.9 0.6 -0.9 0.7 -2.4 0.6 0.23 
  1 
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  8 
1:1 Allocation 
Exclusions 
n = 26,715 
Refused participation 
n = 1,100 
Randomized 
n = 692 
Stratified on extent of DVT and center 
PCDT Group 
n = 336 
 
n = 608 
Did not get PCDT in first 7 days (n=11) 
LEP† done during 24 months (n=20) 
Treatment 
Post-randomization 
failed inclusion (n=1) 
Completed 24 months (n=257) 
Follow-up <24 months (n=79): 
- Death (n=7) 
- Withdrew consent (n=10) 
- Lost to follow-up (n=62) 
 
Follow-up 
 n = 336 (modified ITT) 
n = 325 (per-protocol) 
Analyzed 
Completed 4 assessments (n=215) 
Completed 1-3 assessments (n=93) 





n = 355  
Received PCDT in first 7 days (n=5) 
LEP† done during 24 months (n=12) 
Completed 24 months (n=243) 
Follow-up <24 months (n=112): 
- Death (n=8) 
- Withdrew consent (n=18) 
- Lost to follow-up (n=86) 
 n = 355 (modified ITT) 
n = 350 (per-protocol) 
Completed 4 assessments (n=194) 
Completed 1-3 assessments (n=109) 
Missed all 4 assessments (n=52) 
Met Inclusion 
n = 28,507 
† LEP denotes late endovascular procedure. 
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Figure 2: VEINES-QOL model-fitted change scores (Baseline to 24 months) treatment effects 1 
within subgroups. SE, standard error; CI, confidence interval 2 











< 65, n = 555 
≥ 65, n = 119 
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  < 25, n = 113 
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< 1 week, n=351 
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Iliofemoral, n=382 
Femoropopliteal, n=292 
None (0-4), n=122 
Mild (5-9), n=235 
Moderate (10-14), n=190 
Severe (≥ 15), n=127 
PCDT vs No PCDT 
Mean (SE) 
29.4 (1.4) vs. 24.9 (1.2) 
20.5 (2.4) vs. 18.9 (2.4) 
31.7 (2.0) vs. 27.1 (1.7) 
25.4 (1.5) vs. 21.8 (1.4) 
29.0 (1.4) vs. 24.9 (1.2) 
23.5 (2.7) vs. 20.1 (2.5) 
31.2 (3.6) vs. 26.9 (2.5) 
28.2 (2.3) vs. 23.2 (1.8) 
26.7 (1.5) vs. 23.2 (1.6) 
24.9 (1.7) vs. 21.9 (1.5) 
31.5 (1.8) vs. 25.8 (1.5) 
28.5 (1.9) vs. 23.0 (2.0) 
27.4 (2.2) vs. 25.7 (2.2) 
21.4 (2.7) vs. 16.9 (2.2) 
24.2 (2.1) vs. 22.9 (1.9) 
33.0 (2.1) vs. 29.5 (2.0) 
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Figure 3: LOESS-smoothed estimates of the model-predicted VEINES-QOL mean change-1 
from-baseline scores at each assessment for the 4 groups defined by extent of DVT and 2 
treatment arm. IF, iliofemoral DVT; FP, isolated femoral-popliteal DVT 3 
 4 
 5 
   6 
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Figure 4. VEINES-QOL Incremental Change by Group (Model-fitted Estimates). IF, iliofemoral 1 
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VEINES-QOL score (0-100 range) – higher is better; SF-36 major scales: physical component score (PCS) and mental 
component score (MCS) (0-100 range)  – higher is better, with a difference of 4 points considered clinically meaningful 






Footnotes for Supplementary Tables D-I 
* statistical comparison using an unpaired t-test (based on the raw data) 
† statistical comparison using a Wald test using a growth curve model with piece-wise linear regression over time 
adjusted for stratification factors: extent of DVT (iliofemoral vs. femoropopliteal) and center, and baseline covariates: 
age, sex, BMI, Villalta score. 
VEINES-QOL score (0-100 range) – higher is better; SF-36 major scales: physical component score (PCS) and mental 
component score (MCS) – higher is better, with a difference of 4 points considered clinically meaningful 
‡ Auxiliary variables used in multiple imputation: for SF-36 (MCS and PCS), age (continuous), sex, race, BMI 
(continuous) and all available SF-36 scores from previous visits; for VEINES-QOL, age (continuous), sex, BMI, 
extent of index DVT and all available VEINES scores from previous visits 
MI, multiple imputation; SE, standard error; Est, estimate; CI, confidence interval 
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PCDT No PCDT PCDT – No PCDT 
n Mean SE n Mean SE Est. SE 95% CI 
VEINES-QOL:           
At Baseline 329 50.3 1.3 347 51.4 1.3 -1.1 1.8 -4.7 2.5 
At 1 month 318 64.9 1.4 320 60.3 1.4 4.6 1.9 0.8 8.5 
At 6 months 290 77.0 1.4 282 73.1 1.4 3.9 2.0 0.1 7.8 
At 12 months 270 77.8 1.4 256 77.7 1.4 0.1 2.0 -3.8 4.1 
At 18 months 245 78.9 1.5 222 78.8 1.5 0.1 2.1 -4.0 4.3 
At 24 months 250 80.3 1.3 230 77.9 1.5 2.4 2.0 -1.5 6.3 
VEINES-Sym:           
At Baseline 327 56.7 1.4 347 56.7 1.4 0.0 1.9 -3.8 3.8 
At 1 month 317 69.5 1.4 320 66.3 1.4 3.2 2.0 -0.6 7.0 
At 6 months 290 77.8 1.3 282 73.7 1.5 4.1 2.0 0.2 7.9 
At 12 months 270 76.5 1.4 256 76.4 1.4 0.1 2.0 -3.9 4.0 
At 18 months 245 77.3 1.5 222 76.6 1.6 0.7 2.2 -3.6 5.1 
At 24 months 250 79.9 1.3 230 77.4 1.5 2.5 2.0 -1.4 6.3 
SF-36 PCS:            
At Baseline 328 35.7 0.6 347 37.1 0.6 -1.4 0.9 -3.1 0.3 
At 1 month 318 42.9 0.6 320 41.9 0.6 1.0 0.9 -0.7 2.7 
At 6 months 290 47.1 0.7 282 46.3 0.7 0.8 0.9 -1.0 2.7 
At 12 months 270 48.0 0.7 256 47.5 0.7 0.5 1.0 -1.4 2.4 
At 18 months 244 47.9 0.7 222 48.7 0.7 -0.8 1.0 -2.8 1.2 
At 24 months 250 48.1 0.7 230 48.4 0.7 -0.4 1.0 -2.3 1.6 
SF-36 MCS:           
At Baseline 329 48.2 0.7 347 48.4 0.7 -0.1 1.0 -2.1 1.9 
At 1 month 318 48.2 0.7 320 48.4 0.7 -0.2 1.0 -2.1 1.7 
At 6 months 290 50.1 0.7 282 51.2 0.6 -1.2 0.9 -3.0 0.7 
At 12 months 270 50.4 0.7 256 51.8 0.7 -1.4 1.0 -3.3 0.6 
At 18 months 244 50.9 0.7 222 52.7 0.6 -1.8 1.0 -3.7 0.1 






Table B. Iliofemoral DVT Subgroup: Disease-specific and general QOL mean scores at each assessment point, 
according to treatment and treatment difference 
 
Outcome Measure 
PCDT No PCDT PCDT – No PCDT 
n Mean SE n Mean SE Est. SE 95% CI 
VEINES-QOL:           
At Baseline 193 48.0 1.7 190 49.2 1.7 -1.2 2.4 -6.0 3.5 
At 1 month 181 63.5 1.8 173 55.1 1.9 8.4 2.6 3.3 13.6 
At 6 months 169 76.4 1.9 147 68.6 2.0 7.9 2.8 2.4 13.3 
At 12 months 154 76.2 2.0 135 75.1 2.0 1.1 2.8 -4.5 6.6 
At 18 months 139 77.5 1.9 123 76.4 2.1 1.1 2.9 -4.5 6.7 
At 24 months 141 78.7 1.8 129 75.2 2.1 3.5 2.8 -2.0 9.0 
VEINES-Sym:           
At Baseline 191 55.6 1.7 190 56.0 1.9 -0.4 2.6 -5.4 4.6 
At 1 month 180 68.8 1.8 173 62.6 2.0 6.2 2.7 0.9 11.5 
At 6 months 169 77.5 1.8 147 70.7 2.1 6.7 2.7 1.3 12.1 
At 12 months 154 75.2 1.9 135 74.8 2.1 0.4 2.8 -5.2 5.9 
At 18 months 139 77.0 1.9 123 75.0 2.3 1.9 3.0 -3.9 7.8 
At 24 months 141 79.1 1.7 129 75.3 2.1 3.8 2.7 -1.6 9.1 
SF-36 PCS:            
At Baseline 193 34.8 0.9 190 36.5 0.8 -1.7 1.2 -4.0 0.6 
At 1 month 181 42.9 0.8 173 40.2 0.8 2.7 1.2 0.4 4.9 
At 6 months 169 46.4 0.9 147 44.7 1.0 1.6 1.3 -0.9 4.2 
At 12 months 154 47.0 0.9 135 46.9 0.9 0.0 1.3 -2.6 2.6 
At 18 months 138 46.8 1.0 123 48.1 1.0 -1.3 1.4 -4.1 1.4 
At 24 months 141 46.6 1.0 129 48.2 0.9 -1.6 1.4 -4.2 1.1 
SF-36 MCS:           
At Baseline 193 47.1 0.9 190 45.7 1.0 1.4 1.4 -1.3 4.1 
At 1 month 181 47.2 1.0 173 46.2 1.0 1.1 1.4 -1.7 3.8 
At 6 months 169 49.3 0.9 147 50.0 1.0 -0.7 1.3 -3.4 1.9 
At 12 months 154 49.1 1.0 135 50.9 1.0 -1.8 1.4 -4.5 1.0 
At 18 months 138 49.2 1.0 123 51.0 1.0 -1.8 1.4 -4.6 1.0 





Table C. Femoral-popliteal DVT Subgroup: Disease-specific and general QOL mean scores at each assessment 
point, according to treatment and treatment difference  
 
Outcome Measure 
PCDT No PCDT PCDT – No PCDT 
n Mean SE n Mean SE Est. SE 95% CI 
VEINES-QOL:           
At Baseline 136 53.5 2.0 157 54.1 1.9 -0.5 2.8 -6.0 5.0 
At 1 month 137 66.8 2.1 147 66.4 1.9 0.3 2.8 -5.2 5.8 
At 6 months 121 77.8 2.0 135 78.0 1.8 -0.1 2.7 -5.4 5.2 
At 12 months 116 80.0 2.0 121 80.6 2.0 -0.6 2.8 -6.2 5.0 
At 18 months 106 80.8 2.2 99 81.8 2.1 -1.0 3.1 -7.0 5.1 
At 24 months 109 82.4 1.9 101 81.4 1.9 1.0 2.7 -4.4 6.4 
VEINES-Sym:           
At Baseline 136 58.3 2.1 157 57.7 2.0 0.7 3.0 -5.2 6.5 
At 1 month 137 70.3 2.1 147 70.5 1.9 -0.2 2.8 -5.7 5.3 
At 6 months 121 78.2 2.0 135 77.0 2.0 1.2 2.8 -4.3 6.8 
At 12 months 116 78.1 2.1 121 78.1 2.0 0.0 2.9 -5.6 5.6 
At 18 months 106 77.7 2.4 99 78.5 2.3 -0.8 3.3 -7.3 5.7 
At 24 months 109 80.9 2.0 101 80.1 2.0 0.8 2.9 -4.9 6.4 
SF-36 PCS:            
At Baseline 135 37.0 0.9 157 37.8 0.9 -0.8 1.3 -3.4 1.7 
At 1 month 137 43.0 1.0 147 44.0 0.9 -1.0 1.3 -3.6 1.7 
At 6 months 121 48.2 1.0 135 48.0 1.0 0.2 1.4 -2.5 2.9 
At 12 months 116 49.3 0.9 121 48.1 1.0 1.3 1.4 -1.5 4.0 
At 18 months 106 49.4 1.0 99 49.5 1.1 -0.1 1.5 -3.0 2.9 
At 24 months 109 49.9 0.9 101 48.8 1.1 1.1 1.4 -1.6 3.9 
SF-36 MCS:           
At Baseline 136 49.8 1.1 157 51.6 0.9 -1.8 1.4 -4.6 1.1 
At 1 month 137 49.5 1.0 147 51.0 0.8 -1.6 1.3 -4.2 1.0 
At 6 months 121 51.2 1.0 135 52.6 0.8 -1.4 1.3 -3.9 1.2 
At 12 months 116 52.1 1.0 121 52.8 0.9 -0.7 1.4 -3.4 2.0 
At 18 months 106 53.1 1.0 99 54.8 0.8 -1.7 1.3 -4.2 0.8 




Table D. All patients: Disease-specific QOL (VEINES-QOL, VEINES-Sym) results according to treatment: Per 
Protocol Analysis Set 
Outcome Measure 
PCDT No PCDT PCDT – No PCDT Difference 
n Mean SE n Mean SE Est. SE 95% CI p 
VEINES-QOL:            
At Baseline 319 50.3 1.3 342 51.4 1.3 -1.1 1.9 -4.8 2.5  
At 30 days 309 65.1 1.4 316 60.4 1.4 4.7 2.0 0.8 8.6  
At 6 months 281 77.0 1.4 280 73.0 1.4 4.0 2.0 0.1 7.9  
At 12 months 262 77.9 1.5 253 77.7 1.4 0.3 2.0 -3.8 4.3  
At 18 months 237 79.1 1.5 219 78.6 1.5 0.5 2.1 -3.7 4.7  
At 24 months 243 80.6 1.3 227 77.8 1.5 2.9 2.0 -1.1 6.8  
Change baseline to 30 days            
Raw data* 305 14.4 1.4 310 8.5 1.2 5.9 1.9 2.2 9.5 0.0017 
Model-fitted†  15.0 1.3  9.0 1.3 6.0 1.7 2.7 9.3 0.0004 
Model-fitted using MI‡  15.3 1.3  8.8 1.3 6.5 1.7 3.2 9.9 0.0001 
Change baseline to 6 months            
Raw data* 278 26.0 1.6 275 21.2 1.5 4.8 2.2 0.5 9.0 0.03 
Model-fitted†  26.6 1.3  21.4 1.3 5.1 1.7 1.8 8.5 0.0029 
Model-fitted using MI‡  27.2 1.4  21.4 1.4 5.8 1.8 2.3 9.3 0.0013 
Change baseline to 12 months            
Raw data* 259 26.2 1.7 249 25.1 1.6 1.1 2.3 -3.4 5.6 0.64 
Model-fitted†  27.0 1.4  25.2 1.4 1.8 1.7 -1.6 5.1 0.31 
Model-fitted using MI‡  27.4 1.4  25.7 1.4 1.7 1.8 -1.8 5.3 0.33 
Change baseline to 18 months            
Raw data* 236 27.6 1.8 217 25.3 1.7 2.3 2.5 -2.6 7.2 0.36 
Model-fitted†  27.7 1.3  24.6 1.4 3.1 1.7 -0.2 6.4 0.06 
Model-fitted using MI‡  28.4 1.3  25.2 1.4 3.2 1.7 -0.2 6.6 0.06 
Change baseline to 24 months            
Raw data* 242 27.8 1.8 224 23.9 1.8 3.9 2.5 -1.0 8.9 0.12 
Model-fitted†  28.4 1.5  24.0 1.5 4.5 1.9 0.7 8.3 0.02 




Table D, continued 
Outcome Measure 
PCDT No PCDT PCDT – No PCDT Difference 
n Mean SE n Mean SE Est. SE 95% CI p 
VEINES-Sym:            
At Baseline 317 56.8 1.4 342 56.6 1.4 0.2 2.0 -3.7 4.1  
At 30 days 308 69.7 1.4 316 66.2 1.4 3.5 2.0 -0.4 7.4  
At 6 months 281 77.6 1.4 280 73.6 1.5 4.0 2.0 0.1 7.9  
At 12 months 262 76.5 1.4 253 76.3 1.5 0.1 2.0 -3.9 4.1  
At 18 months 237 77.3 1.5 219 76.4 1.6 0.9 2.2 -3.5 5.4  
At 24 months 243 79.9 1.3 227 77.2 1.5 2.7 2.0 -1.2 6.6  
Change baseline to 30 days            
Raw data* 302 12.3 1.5 310 8.8 1.4 3.5 2.0 -0.4 7.4 0.08 
Model-fitted†  13.1 1.5  9.7 1.5 3.5 2.1 -0.7 7.6 0.10 
Model-fitted using MI‡  13.3 1.6  9.3 1.5 4.0 2.1 -0.2 8.2 0.06 
Change baseline to 6 months            
Raw data* 276 20.1 1.6 275 16.2 1.5 3.9 2.2 -0.5 8.2 0.08 
Model-fitted†  20.9 1.5  16.9 1.5 4.0 2.2 -0.3 8.2 0.07 
Model-fitted using MI‡  21.3 1.6  16.6 1.5 4.7 2.3 0.3 9.1 0.04 
Change baseline to 12 months            
Raw data* 258 18.1 1.7 249 18.1 1.6 0.0 2.3 -4.6 4.5 0.99 
Model-fitted†  19.0 1.5  18.3 1.5 0.7 2.2 -3.6 5.0 0.75 
Model-fitted using MI‡  19.2 1.6  18.4 1.6 0.8 2.2 -3.4 5.0 0.71 
Change baseline to 18 months            
Raw data* 235 19.3 1.8 217 18.0 1.9 1.3 2.6 -3.8 6.5 0.62 
Model-fitted†  20.1 1.5  18.3 1.5 1.8 2.1 -2.3 6.0 0.39 
Model-fitted using MI‡  20.6 1.5  18.4 1.5 2.2 2.1 -1.9 6.3 0.29 
Change baseline to 24 months            
Raw data* 241 20.7 1.7 224 18.1 1.7 2.6 2.4 -2.2 7.3 0.29 
Model-fitted†  21.2 1.7  18.2 1.7 3.0 2.4 -1.6 7.6 0.21 




Table E. All patients: General QOL (SF-36 PCS and MCS) results according to treatment 
Per Protocol Analysis Set 
Outcome Measure 
PCDT No PCDT PCDT – No PCDT Difference 
n Mean SE n Mean SE Est. SE 95% CI p 
SF-36 PCS:             
At Baseline 318 35.6 0.6 342 37.1 0.6 -1.5 0.9 -3.2 0.2  
At 30 days 309 42.9 0.6 316 42.0 0.6 0.9 0.9 -0.9 2.6  
At 6 months 281 47.0 0.7 280 46.3 0.7 0.7 1.0 -1.2 2.6  
At 12 months 262 47.9 0.7 253 47.5 0.7 0.4 1.0 -1.5 2.3  
At 18 months 236 48.0 0.7 219 48.7 0.7 -0.7 1.0 -2.7 1.4  
At 24 months 243 48.2 0.7 227 48.4 0.7 -0.2 1.0 -2.1 1.8  
Change baseline to 30 days            
Raw data* 304 7.3 0.6 310 4.9 0.6 2.3 0.9 0.6 4.1 0.0083 
Model-fitted†  7.5 0.7  5.1 0.7 2.3 1.0 0.5 4.2 0.01 
Model-fitted using MI‡  7.6 0.7  5.0 0.7 2.6 1.0 0.7 4.5 0.0080 
Change baseline to 6 months            
Raw data* 278 10.8 0.8 275 9.5 0.7 1.4 1.1 -0.8 3.5 0.21 
Model-fitted†  11.4 0.7  9.7 0.7 1.7 1.0 -0.1 3.6 0.07 
Model-fitted using MI‡  11.7 0.7  9.6 0.7 2.1 1.0 0.2 4.0 0.03 
Change baseline to 12 months            
Raw data* 258 11.7 0.8 249 10.4 0.8 1.3 1.1 -1.0 3.5 0.27 
Model-fitted†  11.6 0.7  10.0 0.7 1.6 1.0 -0.3 3.4 0.10 
Model-fitted using MI‡  11.9 0.7  10.1 0.7 1.8 1.0 -0.1 3.6 0.06 
Change baseline to 18 months            
Raw data* 234 12.1 0.9 217 11.5 0.9 0.6 1.2 -1.8 3.0 0.62 
Model-fitted†  11.7 0.7  10.3 0.7 1.4 1.0 -0.6 3.4 0.17 
Model-fitted using MI‡  12.0 0.7  10.6 0.7 1.5 1.0 -0.5 3.4 0.14 
Change baseline to 24 months            
Raw data* 241 11.9 0.9 224 10.9 0.9 1.0 1.3 -1.5 3.4 0.44 
Model-fitted†  11.9 0.8  10.6 0.8 1.3 1.2 -1.0 3.5 0.28 




Table E, continued 
Outcome Measure 
PCDT No PCDT PCDT – No PCDT Difference 
n Mean SE n Mean SE Est. SE 95% CI p 
SF-36 MCS:            
At Baseline 319 48.2 0.7 342 48.4 0.7 -0.2 1.0 -2.2 1.9  
At 30 days 309 48.3 0.7 316 48.4 0.7 0.0 1.0 -2.0 1.9  
At 6 months 281 50.1 0.7 280 51.2 0.7 -1.1 1.0 -3.0 0.8  
At 12 months 262 50.6 0.7 253 51.8 0.7 -1.2 1.0 -3.1 0.8  
At 18 months 236 51.1 0.7 219 52.7 0.7 -1.6 1.0 -3.5 0.3  
At 24 months 243 52.3 0.6 227 53.2 0.6 -0.9 0.9 -2.6 0.8  
Change baseline to 30 days            
Raw data* 305 0.0 0.7 310 -0.6 0.7 0.5 1.0 -1.3 2.4 0.57 
Model-fitted†  0.3 0.1  0.4 0.1 -0.1 0.1 -0.3 0.1 0.44 
Model-fitted using MI‡  0.3 0.1  0.5 0.1 -0.2 0.1 -0.4 0.0 0.11 
Change baseline to 6 months            
Raw data* 278 1.8 0.7 275 1.6 0.8 0.2 1.1 -1.9 2.3 0.84 
Model-fitted†  1.8 0.5  2.3 0.5 -0.5 0.7 -1.9 0.8 0.44 
Model-fitted using MI‡  1.8 0.6  2.9 0.5 -1.2 0.7 -2.6 0.3 0.11 
Change baseline to 12 months            
Raw data* 259 1.9 0.8 249 1.6 0.8 0.3 1.1 -1.9 2.5 0.78 
Model-fitted† . 2.2 0.5  2.7 0.5 -0.5 0.6 -1.7 0.6 0.37 
Model-fitted using MI‡ . 2.2 0.5  3.3 0.5 -1.0 0.6 -2.2 0.1 0.09 
Change baseline to 18 months            
Raw data* 235 2.2 0.9 217 2.1 0.8 0.1 1.2 -2.3 2.4 0.96 
Model-fitted†  2.6 0.5  3.1 0.5 -0.5 0.6 -1.7 0.7 0.39 
Model-fitted using MI‡  2.7 0.5  3.6 0.5 -0.9 0.6 -2.1 0.3 0.13 
Change baseline to 24 months            
Raw data* 242 3.1 0.8 224 2.9 0.9 0.2 1.1 -2.1 2.4 0.88 
Model-fitted†  3.1 0.6  3.5 0.6 -0.5 0.7 -1.9 0.9 0.50 






Table F.  Iliofemoral DVT Subgroup: Disease-specific QOL (VEINES QOL, VEINES-Sym) results according to treatment: Per 
Protocol Analysis Set 
Outcome Measure 
PCDT No PCDT PCDT – No PCDT Difference 
n Mean SE n Mean SE Est. SE 95% CI p 
VEINES-QOL:            
At Baseline 188 48.1 1.7 186 49.2 1.8 -1.1 2.5 -6.0 3.7  
At 30 days 177 64.0 1.9 170 55.1 1.9 8.9 2.7 3.6 14.1  
At 6 months 165 76.6 1.9 146 68.4 2.1 8.2 2.8 2.8 13.7  
At 12 months 151 76.6 2.0 133 75.1 2.0 1.5 2.8 -4.0 7.1  
At 18 months 135 78.1 1.9 121 76.0 2.1 2.1 2.9 -3.5 7.8  
At 24 months 138 79.4 1.8 127 74.8 2.2 4.6 2.8 -0.9 10.1  
Change baseline to 30 days            
Raw data* 176 16.0 1.8 166 5.2 1.8 10.8 2.5 5.8 15.7 <0.0001 
Model-fitted†  16.6 1.7  6.1 1.7 10.5 2.2 6.2 14.8 <0.0001 
Model-fitted using MI‡  16.6 1.7  5.8 1.7 10.8 2.2 6.5 15.1 <0.0001 
Change baseline to 6 months            
Raw data* 164 27.3 2.1 143 18.3 2.1 9.1 3.0 3.2 14.9 0.0024 
Model-fitted†  27.9 1.7  18.7 1.8 9.2 2.2 4.8 13.6 <0.0001 
Model-fitted using MI‡  28.4 1.8  18.6 1.8 9.8 2.2 5.4 14.2 <0.0001 
Change baseline to 12 months            
Raw data* 150 27.2 2.2 131 24.3 2.3 2.9 3.2 -3.3 9.2 0.36 
Model-fitted†  28.1 1.7  23.1 1.8 4.9 2.2 0.6 9.3 0.03 
Model-fitted using MI‡  28.5 1.7  23.3 1.8 5.2 2.2 0.8 9.5 0.02 
Change baseline to 18 months            
Raw data* 135 28.9 2.4 120 25.4 2.4 3.5 3.4 -3.2 10.2 0.30 
Model-fitted†  28.6 1.7  22.9 1.8 5.8 2.2 1.5 10.1 0.0086 
Model-fitted using MI‡  29.4 1.7  23.2 1.8 6.3 2.2 1.9 10.6 0.0046 
Change baseline to 24 months            
Raw data* 138 28.9 2.3 126 22.8 2.6 6.1 3.5 -0.8 12.9 0.08 
Model-fitted†  29.2 1.9  22.6 2.0 6.6 2.4 1.8 11.3 0.0067 




Table F, continued 
Outcome Measure 
PCDT No PCDT PCDT – No PCDT Difference 
n Mean SE n Mean SE Est. SE 95% CI p 
VEINES-Sym:            
At Baseline 186 55.7 1.8 186 55.8 1.9 -0.1 2.6 -5.2 5.1  
At 30 days 176 69.3 1.9 170 62.5 2.0 6.8 2.7 1.5 12.2  
At 6 months 165 77.4 1.8 146 70.6 2.1 6.8 2.8 1.4 12.3  
At 12 months 151 75.3 1.9 133 74.7 2.1 0.6 2.8 -5.0 6.2  
At 18 months 135 77.3 2.0 121 74.7 2.3 2.6 3.0 -3.4 8.5  
At 24 months 138 79.5 1.7 127 75.0 2.2 4.6 2.7 -0.8 9.9  
Change baseline to 30 days            
Raw data* 173 13.2 1.9 166 5.5 2.0 7.6 2.7 2.2 13.0 0.0057 
Model-fitted†  14.1 1.8  6.4 1.8 7.7 2.3 3.2 12.1 0.0007 
Model-fitted using MI‡  13.9 1.8  6.2 1.8 7.7 2.2 3.3 12.0 0.0006 
Change baseline to 6 months            
Raw data* 162 20.0 2.1 143 13.4 2.1 6.6 3.0 0.6 12.5 0.03 
Model-fitted†  21.8 1.8  13.8 1.8 8.1 2.3 3.6 12.5 0.0004 
Model-fitted using MI‡  22.0 1.8  13.7 1.8 8.4 2.3 3.8 13.0 0.0004 
Change baseline to 12 months            
Raw data* 149 18.2 2.2 131 17.0 2.3 1.2 3.2 -5.1 7.5 0.71 
Model-fitted†  20.0 1.8  15.6 1.8 4.4 2.2 0.0 8.8 0.05 
Model-fitted using MI‡  20.0 1.8  15.7 1.8 4.3 2.1 0.1 8.5 0.04 
Change baseline to 18 months            
Raw data* 134 20.4 2.4 120 18.0 2.6 2.5 3.5 -4.5 9.4 0.49 
Model-fitted†  21.0 1.7  15.8 1.8 5.3 2.2 0.9 9.6 0.02 
Model-fitted using MI‡  21.5 1.8  15.9 1.8 5.6 2.1 1.5 9.7 0.0081 
Change baseline to 24 months            
Raw data* 137 21.1 2.2 126 16.9 2.5 4.2 3.3 -2.4 10.7 0.21 
Model-fitted†  22.1 1.9  15.9 2.0 6.1 2.4 1.4 10.9 0.01 






Table G. Iliofemoral DVT Subgroup: General QOL (SF-36 PCS and MCS) results according to treatment: Per Protocol 
Analysis Set 
Outcome Measure 
PCDT No PCDT PCDT – No PCDT Difference 
n Mean SE n Mean SE Est. SE 95% CI p 
SF-36 PCS:             
At Baseline 188 34.9 0.9 186 36.5 0.8 -1.7 1.2 -4.0 0.7  
At 30 days 177 43.0 0.8 170 40.3 0.8 2.7 1.2 0.4 5.0  
At 6 months 165 46.4 0.9 146 44.7 1.0 1.7 1.3 -0.8 4.3  
At 12 months 151 47.1 0.9 133 47.0 0.9 0.1 1.3 -2.5 2.7  
At 18 months 134 47.0 1.0 121 48.0 1.0 -1.0 1.4 -3.7 1.8  
At 24 months 138 47.0 1.0 127 48.0 0.9 -1.0 1.4 -3.7 1.6  
Change baseline to 30 days            
Raw data* 176 8.3 0.8 166 3.6 0.9 4.7 1.2 2.3 7.1 0.0002 
Model-fitted†  7.8 0.8  4.5 0.8 3.3 1.0 1.4 5.2 0.0009 
Model-fitted using MI‡  7.8 0.8  4.5 0.8 3.3 1.0 1.4 5.2 0.0006 
Change baseline to 6 months            
Raw data* 164 11.0 1.0 143 8.1 1.1 3.0 1.5 0.0 5.9 0.05 
Model-fitted†  11.3 0.8  9.4 0.8 1.9 1.0 0.0 3.9 0.05 
Model-fitted using MI‡  11.7 0.8  9.3 0.8 2.3 1.0 0.4 4.3 0.02 
Change baseline to 12 months            
Raw data* 150 11.5 1.1 131 10.4 1.2 1.1 1.7 -2.2 4.4 0.51 
Model-fitted†  11.2 0.8  10.0 0.8 1.3 1.0 -0.6 3.2 0.19 
Model-fitted using MI‡  11.6 0.8  10.1 0.8 1.5 0.9 -0.3 3.3 0.10 
Change baseline to 18 months            
Raw data* 134 11.7 1.2 120 11.7 1.3 0.0 1.7 -3.4 3.4 0.99 
Model-fitted†  11.2 0.8  10.6 0.9 0.6 1.0 -1.4 2.6 0.54 
Model-fitted using MI‡  11.6 0.8  10.9 0.8 0.7 0.9 -1.1 2.6 0.45 
Change baseline to 24 months            
Raw data* 138 11.5 1.2 126 11.0 1.3 0.5 1.8 -2.9 4.0 0.76 
Model-fitted†  11.1 0.9  11.2 0.9 -0.1 1.1 -2.3 2.2 0.96 





Table G, continued 
Outcome Measure 
PCDT No PCDT PCDT – No PCDT Difference 
n Mean SE n Mean SE Est. SE 95% CI p 
SF-36 MCS:            
At Baseline 188 47.0 1.0 186 45.7 1.0 1.3 1.4 -1.5 4.0  
At 30 days 177 47.4 1.0 170 46.1 1.0 1.4 1.4 -1.4 4.1  
At 6 months 165 49.4 0.9 146 50.0 1.0 -0.6 1.4 -3.3 2.1  
At 12 months 151 49.5 1.0 133 50.8 1.0 -1.4 1.4 -4.1 1.4  
At 18 months 134 49.7 1.0 121 50.9 1.0 -1.2 1.4 -4.0 1.5  
At 24 months 138 51.7 0.9 127 51.7 0.9 0.1 1.2 -2.4 2.5  
Change baseline to 30 days            
Raw data* 176 0.4 0.9 166 0.1 1.0 0.3 1.3 -2.4 3.0 0.82 
Model-fitted†  0.3 0.1  0.4 0.1 -0.1 0.1 -0.3 0.2 0.60 
Model-fitted using MI‡  0.3 0.1  0.5 0.1 -0.2 0.1 -0.4 0.1 0.20 
Change baseline to 6 months            
Raw data* 164 2.1 0.9 143 3.0 1.1 -0.9 1.5 -3.8 2.0 0.53 
Model-fitted†  1.8 0.6  2.2 0.6 -0.4 0.8 -2.0 1.1 0.60 
Model-fitted using MI‡  1.8 0.6  2.8 0.6 -1.0 0.8 -2.6 0.6 0.20 
Change baseline to 12 months            
Raw data* 150 2.3 1.0 131 3.3 1.2 -0.9 1.5 -4.0 2.1 0.55 
Model-fitted†  2.2 0.5  2.6 0.5 -0.4 0.7 -1.8 0.9 0.51 
Model-fitted using MI‡  2.2 0.5  3.2 0.5 -0.9 0.7 -2.2 0.4 0.16 
Change baseline to 18 months            
Raw data* 134 2.1 1.2 120 3.2 1.2 -1.2 1.7 -4.5 2.2 0.49 
Model-fitted†  2.6 0.5  3.1 0.5 -0.5 0.6 -1.8 0.8 0.46 
Model-fitted using MI‡  2.7 0.5  3.5 0.5 -0.8 0.6 -2.1 0.4 0.19 
Change baseline to 24 months            
Raw data* 138 4.1 1.0 126 3.8 1.2 0.3 1.6 -2.8 3.5 0.83 
Model-fitted†  3.0 0.6  3.5 0.6 -0.5 0.7 -1.9 0.9 0.48 







Table H. Femoral-popliteal DVT Subgroup: Disease-specific QOL (VEINES-QOL, VEINES-Sym) results according to 
treatment: Per Protocol Analysis Set 
Outcome Measure 
PCDT No PCDT PCDT – No PCDT Difference 
n Mean SE n Mean SE Est. SE 95% CI p 
VEINES-QOL:            
At Baseline 131 53.4 2.0 156 54.0 1.9 -0.6 2.8 -6.2 4.9  
At 30 days 132 66.6 2.1 146 66.5 1.9 0.1 2.8 -5.5 5.6  
At 6 months 116 77.4 2.0 134 78.0 1.9 -0.6 2.7 -6.0 4.8  
At 12 months 111 79.7 2.1 120 80.6 2.0 -0.9 2.9 -6.6 4.9  
At 18 months 102 80.4 2.3 98 81.8 2.2 -1.4 3.2 -7.6 4.8  
At 24 months 105 82.2 2.0 100 81.5 1.9 0.7 2.8 -4.8 6.2  
Change baseline to 30 days            
Raw data* 129 12.3 2.3 144 12.4 1.6 -0.1 2.7 -5.5 5.3 0.97 
Model-fitted†  13.0 1.9  12.6 1.8 0.5 2.4 -4.3 5.3 0.85 
Model-fitted using MI‡  13.6 2.0  12.5 1.9 1.1 2.5 -3.8 6.0 0.67 
Change baseline to 6 months            
Raw data* 114 24.1 2.5 132 24.4 2.0 -0.3 3.1 -6.5 5.8 0.91 
Model-fitted†  24.7 2.0  24.4 1.9 0.3 2.4 -4.5 5.1 0.90 
Model-fitted using MI‡  25.6 2.0  24.7 1.9 0.9 2.5 -4.1 5.8 0.73 
Change baseline to 12 months            
Raw data* 109 24.7 2.5 118 26.0 2.1 -1.3 3.3 -7.7 5.2 0.70 
Model-fitted†  25.4 2.0  28.0 1.9 -2.6 2.4 -7.4 2.1 0.28 
Model-fitted using MI‡  25.8 2.0  28.7 1.9 -2.8 2.4 -7.6 1.9 0.24 
Change baseline to 18 months            
Raw data* 101 25.8 2.8 97 25.1 2.5 0.7 3.8 -6.7 8.1 0.85 
Model-fitted†  26.4 2.0  26.8 1.9 -0.5 2.5 -5.3 4.3 0.85 
Model-fitted using MI‡  27.0 2.0  27.8 2.0 -0.8 2.4 -5.6 4.0 0.75 
Change baseline to 24 months            
Raw data* 104 26.4 2.7 98 25.2 2.4 1.2 3.6 -6.0 8.3 0.75 
Model-fitted†  27.4 2.2  25.7 2.2 1.7 2.7 -3.7 7.1 0.54 




Table H, continued 
Outcome Measure 
PCDT No PCDT PCDT – No PCDT Difference 
n Mean SE n Mean SE Est. SE 95% CI p 
VEINES-Sym:            
At Baseline 131 58.2 2.2 156 57.5 2.1 0.7 3.0 -5.2 6.6  
At 30 days 132 70.2 2.1 146 70.5 1.9 -0.3 2.8 -5.8 5.3  
At 6 months 116 78.0 2.0 134 77.0 2.0 1.0 2.9 -4.7 6.6  
At 12 months 111 78.0 2.1 120 78.2 2.0 -0.1 2.9 -5.9 5.6  
At 18 months 102 77.4 2.5 98 78.5 2.3 -1.1 3.4 -7.8 5.5  
At 24 months 105 80.5 2.1 100 80.1 2.1 0.4 2.9 -5.4 6.1  
Change baseline to 30 days            
Raw data* 129 11.2 2.3 144 12.6 1.8 -1.4 2.9 -7.2 4.3 0.63 
Model-fitted†  12.7 2.0  12.8 1.9 0.0 2.5 -4.9 4.9 0.99 
Model-fitted using MI‡  13.2 2.1  12.4 2.0 0.8 2.5 -4.2 5.7 0.76 
Change baseline to 6 months            
Raw data* 114 20.2 2.5 132 19.2 2.2 1.0 3.3 -5.6 7.5 0.77 
Model-fitted†  20.5 2.0  19.7 2.0 0.8 2.5 -4.0 5.7 0.73 
Model-fitted using MI‡  21.1 2.1  19.5 2.0 1.7 2.5 -3.3 6.7 0.51 
Change baseline to 12 months            
Raw data* 109 17.9 2.5 118 19.4 2.3 -1.4 3.4 -8.1 5.2 0.67 
Model-fitted†  18.7 2.0  21.0 2.0 -2.3 2.4 -7.1 2.5 0.35 
Model-fitted using MI‡  18.8 2.0  21.0 2.0 -2.2 2.5 -7.1 2.7 0.39 
Change baseline to 18 months            
Raw data* 101 17.9 2.8 97 18.1 2.7 -0.2 3.9 -7.9 7.5 0.96 
Model-fitted†  19.8 2.0  20.7 2.0 -0.9 2.5 -5.7 3.9 0.71 
Model-fitted using MI‡  20.2 2.0  20.8 2.0 -0.6 2.5 -5.5 4.2 0.80 
Change baseline to 24 months            
Raw data* 104 20.1 2.7 98 19.7 2.2 0.5 3.5 -6.4 7.4 0.89 
Model-fitted†  20.9 2.2  20.4 2.2 0.5 2.8 -4.9 5.9 0.86 






Table I. Femoral-popliteal DVT Subgroup: General QOL (SF-36 PCS and MCS) results according to treatment: Per Protocol 
Analysis Set 
Outcome Measure 
PCDT No PCDT PCDT – No PCDT Difference 
n Mean SE n Mean SE Est. SE 95% CI p 
SF-36 PCS:             
At Baseline 130 36.7 0.9 156 37.8 0.9 -1.1 1.3 -3.6 1.5  
At 30 days 132 42.7 1.0 146 44.0 0.9 -1.3 1.3 -3.9 1.4  
At 6 months 116 47.8 1.0 134 48.0 1.0 -0.2 1.4 -3.0 2.5  
At 12 months 111 49.0 1.0 120 48.0 1.0 1.0 1.4 -1.8 3.8  
At 18 months 102 49.3 1.1 98 49.5 1.1 -0.2 1.5 -3.2 2.8  
At 24 months 105 49.8 0.9 100 48.8 1.1 1.0 1.4 -1.8 3.8  
Change baseline to 30 days            
Raw data* 128 5.8 1.0 144 6.4 0.8 -0.6 1.3 -3.1 1.9 0.65 
Model-fitted†  6.2 0.9  6.7 0.9 -0.5 1.1 -2.6 1.7 0.67 
Model-fitted using MI‡  6.3 0.9  6.5 0.9 -0.2 1.1 -2.4 2.0 0.84 
Change baseline to 6 months            
Raw data* 114 10.6 1.2 132 11.0 1.0 -0.4 1.6 -3.5 2.6 0.78 
Model-fitted†  10.2 0.9  11.0 0.9 -0.9 1.1 -3.0 1.3 0.44 
Model-fitted using MI‡  10.5 0.9  10.9 0.9 -0.3 1.1 -2.5 1.9 0.77 
Change baseline to 12 months            
Raw data* 108 11.9 1.1 118 10.5 1.0 1.5 1.5 -1.5 4.5 0.33 
Model-fitted†  10.7 0.9  11.0 0.9 -0.4 1.1 -2.5 1.7 0.74 
Model-fitted using MI‡  11.0 0.9  11.1 0.9 -0.1 1.0 -2.1 2.0 0.95 
Change baseline to 18 months            
Raw data* 100 12.6 1.2 97 11.2 1.2 1.4 1.7 -2.0 4.8 0.42 
Model-fitted†  11.2 1.0  11.1 0.9 0.1 1.1 -2.1 2.4 0.91 
Model-fitted using MI‡  11.4 1.0  11.2 0.9 0.2 1.1 -1.9 2.3 0.86 
Change baseline to 24 months            
Raw data* 103 12.4 1.3 98 10.8 1.2 1.6 1.8 -1.9 5.0 0.38 
Model-fitted†  11.7 1.1  11.1 1.0 0.6 1.3 -1.9 3.1 0.62 




Table I, continued 
Outcome Measure 
PCDT No PCDT PCDT – No PCDT Difference 
n Mean SE n Mean SE Est. SE 95% CI p 
SF-36 MCS:            
At Baseline 131 50.0 1.1 156 51.6 0.9 -1.6 1.5 -4.5 1.3  
At 30 days 132 49.5 1.1 146 51.0 0.9 -1.5 1.4 -4.2 1.2  
At 6 months 116 51.2 1.0 134 52.6 0.8 -1.3 1.3 -3.9 1.2  
At 12 months 111 52.1 1.1 120 52.8 0.9 -0.7 1.4 -3.5 2.1  
At 18 months 102 52.9 1.0 98 54.8 0.8 -1.9 1.3 -4.4 0.6  
At 24 months 105 53.0 0.9 100 55.1 0.7 -2.1 1.1 -4.3 0.1  
Change baseline to 30 days            
Raw data* 129 -0.6 1.1 144 -1.4 0.8 0.7 1.3 -1.9 3.3 0.59 
Model-fitted†  0.3 0.1  0.4 0.1 -0.1 0.1 -0.3 0.2 0.60 
Model-fitted using MI‡  0.3 0.1  0.5 0.1 -0.2 0.1 -0.4 0.1 0.20 
Change baseline to 6 months            
Raw data* 114 1.4 1.2 132 0.0 1.1 1.4 1.6 -1.7 4.5 0.39 
Model-fitted†  1.8 0.6  2.2 0.6 -0.4 0.8 -2.0 1.1 0.60 
Model-fitted using MI‡  1.8 0.6  2.8 0.6 -1.0 0.8 -2.6 0.6 0.20 
Change baseline to 12 months            
Raw data* 109 1.4 1.3 118 -0.2 1.0 1.6 1.7 -1.6 4.9 0.33 
Model-fitted†  2.2 0.5  2.6 0.5 -0.4 0.7 -1.8 0.9 0.51 
Model-fitted using MI‡  2.2 0.5  3.2 0.5 -0.9 0.7 -2.2 0.4 0.16 
Change baseline to 18 months            
Raw data* 101 2.3 1.3 97 0.7 1.1 1.6 1.7 -1.8 4.9 0.36 
Model-fitted†  2.6 0.5  3.1 0.5 -0.5 0.6 -1.8 0.8 0.46 
Model-fitted using MI‡  2.7 0.5  3.5 0.5 -0.8 0.6 -2.1 0.4 0.19 
Change baseline to 24 months            
Raw data* 104 1.7 1.1 98 1.8 1.2 -0.1 1.6 -3.3 3.1 0.95 
Model-fitted†  3.0 0.6  3.5 0.6 -0.5 0.7 -1.9 0.9 0.48 





Table J. Missing QOL Assessments by Visit and Treatment 
Visit 
PCDT No PCDT All 
n % n % n % 
Baseline 7 2% 8 2% 15 2% 
1 month 18 5% 35 10% 53 8% 
6 months 46 14% 73 21% 119 17% 
12 months 66 20% 99 28% 165 24% 
18 months 91 27% 133 37% 224 32% 
24 months 86 26% 125 35% 211 31% 






Interaction terms involving time, treatment and extent of DVT 
in the growth curve models 
For each QOL outcome, interaction terms between treatment and time (one term at each assessment time: 
baseline, 1, 6, 12, 18 and 24 months) were included in the final growth curve model if they maintained statistical 
significance at the 0.05 level. Thus, when treatment-specific slopes differed significantly from each other within an 
assessment interval, the interaction term was retained in the model. 
For the VEINES-QOL/Sym outcomes, the interaction terms at baseline, 1, 6 and 12 months were retained, 
suggesting different rates of change in QOL in the two treatment arms during the interval starting at each of these 
assessment times. For SF-36 PCS, the terms at baseline, 1 and 6 months remained, indicating a similar effect during 
these intervals. For SF-36 MCS, only the terms at baseline and 6 months remained in the model, suggesting only one 
change in slope at 6 months.  
For the models which included interaction terms for the two extent subgroups (iliofemoral, femoral-popliteal), 
the two-factor treatment x time and three-factor treatment x time x extent interactions were assessed concurrently. 
For the VEINES-QOL/Sym outcomes, the treatment x time terms at baseline, 1, 6 and 12 months were retained 
(as above), but only the treatment x time x extent terms at baseline and 1 month remained in the model, suggesting 
that the larger QOL improvement in the PCDT arm compared with the No PCDT arm, was apparent only for those 
with iliofemoral DVT and only during the first month post-randomization. Similarly, for SF-36 PCS, the treatment x 
time terms at baseline, 1 and 6 months were retained (as above), while only the treatment x time x extent terms at 
baseline and 1 month remained in the model. For the SF-36 MCS, only the treatment x time interactions at baseline 
and 6 months remained in the model (as above) since none of the three-factor interactions were significant. 
Collectively, these observations suggest that the effect of improved VEINES-QOL/Sym and SF-36 PCS QOL 
with PCDT in the iliofemoral DVT group was statistically different from the effect in the femoral-popliteal DVT 
group over the first month post-randomization, but not during subsequent time intervals. There were no subgroup 
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